{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:06:02Z","timestamp":1789499162007,"version":"build-2803163510"},"reference-count":29,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Classic Hodgkin lymphoma (cHL) treatment has evolved over recent years, driven by advances in novel agents. In low-income countries with resource constraints, ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy is the cheapest and most curative option. Here we highlight the outcome of the ABVD regimen in adults with classic Hodgkin lymphoma (cHL) and associated factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>A retrospective cohort study conducted at Aga Khan University Hospital, Karachi, Pakistan, from 1st January 2013 to 31st December 2023, included 246 patients (aged 18 years or older at cHL diagnosis) who received ABVD as their first chemotherapy regimen. Median OS and PFS were estimated using the Kaplan-Meier method, and the association between variables was assessed using the log-rank test. Univariate and multivariate analyses were used to identify significant factors using Cox regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median age of our cohort was 35 years, with a male predominance (1.6 male-to-female ratio). Out of 246 patients, 78 (31.7%) had early-stage disease, while 168 (68.3%) had advanced-stage disease. The median overall survival and progression-free survival (PFS) were not reached. Median follow-up duration was 35 months. Two hundred and five (83.3%) patients remained alive at the end of the study. OS and PFS at 2 years were 85.6% and 74.7%, respectively. Factors that significantly affected OS were age, stage, bulky disease, and ECOG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings show that ABVD is still an effective and economical regimen in developing parts of the world and signifies the importance of age, bulky disease, ECOG, stage, and the risk stratification approach.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2478\/jcas-2026-0008","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:34:56Z","timestamp":1789497296000},"page":"50-58","source":"Crossref","is-referenced-by-count":0,"title":["Outcome of Classic Hodgkin Lymphoma Treated with ABVD Regimen- A Single Center Experience"],"prefix":"10.2478","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6837-1858","authenticated-orcid":false,"given":"Nouman Nawaz","family":"Ali","sequence":"first","affiliation":[{"name":"Resident Hematology , Department of Oncology, Aga Khan University Karachi , Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madiha","family":"Noor","sequence":"additional","affiliation":[{"name":"Resident Hematology , Department of Oncology, Aga Khan University Karachi , Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Ali","sequence":"additional","affiliation":[{"name":"Professor Hematology , Department of Pathology and Laboratory Medicine\/Oncology, Aga Khan University Karachi , Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Usman","family":"Shaikh","sequence":"additional","affiliation":[{"name":"Professor Hematology , Department of Pathology and Laboratory Medicine\/Oncology, Aga Khan University Karachi , Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salman Naseem","family":"Adil","sequence":"additional","affiliation":[{"name":"Professor Hematology , Department of Pathology and Laboratory Medicine\/Oncology, Aga Khan University Karachi , Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"2026091518345058771_j_jcas-2026-0008_ref_001","doi-asserted-by":"crossref","unstructured":"Alaggio R, Amador C, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36(7):1720\u201348.","DOI":"10.1038\/s41375-022-01620-2"},{"key":"2026091518345058771_j_jcas-2026-0008_ref_002","doi-asserted-by":"crossref","unstructured":"Sehn LH. Introduction to a review series on Hodgkin lymphoma: change is here. Blood. 2018;131(15):1629\u201330.","DOI":"10.1182\/blood-2018-02-824045"},{"key":"2026091518345058771_j_jcas-2026-0008_ref_003","doi-asserted-by":"crossref","unstructured":"Moskowitz AJ. Optimizing the role of brentuximab vedotin in classical Hodgkin lymphoma therapy. Hematology Am Soc Hematol Educ Program. 2018;2018(1):207\u201312.","DOI":"10.1182\/asheducation-2018.1.207"},{"key":"2026091518345058771_j_jcas-2026-0008_ref_004","doi-asserted-by":"crossref","unstructured":"Cheson BD, Fisher RI, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non- Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201368.","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"2026091518345058771_j_jcas-2026-0008_ref_005","unstructured":"UNDP. Statistical Update 2018 2018 [Available from: http:\/\/report2017.archive.s3-website-us-east-1.amazonaws.com."},{"key":"2026091518345058771_j_jcas-2026-0008_ref_006","doi-asserted-by":"crossref","unstructured":"Pan T, Zhang J, et al. Global burden and trends of hematologic malignancies based on Global Cancer Observatory 2022 and Global Burden of Disease 2021. Experimental Hematology & Oncology. 2025;14(1):98.","DOI":"10.1186\/s40164-025-00684-x"},{"key":"2026091518345058771_j_jcas-2026-0008_ref_007","doi-asserted-by":"crossref","unstructured":"Suttantapidok S, Kungwankiattichai S, et al. Treatment outcomes of ABVD in classical Hodgkin lymphoma patients from Thailand without procarbazine access. Sci Rep. 2025;15(1):22211.","DOI":"10.1038\/s41598-025-07187-z"},{"key":"2026091518345058771_j_jcas-2026-0008_ref_008","doi-asserted-by":"crossref","unstructured":"Mponda M, Kudowa E, et al. Safety, efficacy, and affordability of ABVD for Hodgkin lymphoma in Malawi: a prospective cohort study. EClinicalMedicine. 2024;69:102480.","DOI":"10.1016\/j.eclinm.2024.102480"},{"key":"2026091518345058771_j_jcas-2026-0008_ref_009","doi-asserted-by":"crossref","unstructured":"Campo E, Swerdlow SH, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019\u201332.","DOI":"10.1182\/blood-2011-01-293050"},{"key":"2026091518345058771_j_jcas-2026-0008_ref_010","unstructured":"Swerdlow SH, editor WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues2017."},{"key":"2026091518345058771_j_jcas-2026-0008_ref_011","unstructured":"Network NCC. Hodgkin Lymphoma (Version 2.2025) 2025 [Available from: https:\/\/www.nccn.org\/login?ReturnURL=https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hodgkins.pdf"},{"key":"2026091518345058771_j_jcas-2026-0008_ref_012","doi-asserted-by":"crossref","unstructured":"Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin\u2019s disease. International Prognostic Factors Project on Advanced Hodgkin\u2019s Disease. N Engl J Med. 1998;339(21):1506\u201314.","DOI":"10.1056\/NEJM199811193392104"},{"key":"2026091518345058771_j_jcas-2026-0008_ref_013","doi-asserted-by":"crossref","unstructured":"Cheson BD, Horning SJ, et al. Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4):1244.","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"2026091518345058771_j_jcas-2026-0008_ref_014","doi-asserted-by":"crossref","unstructured":"Tadmor T, Bari A, et al. Absolute Monocyte Count and Lymphocyte-Monocyte Ratio Predict Outcome in Nodular Sclerosis Hodgkin Lymphoma: Evaluation Based on Data From 1450 Patients. Mayo Clin Proc. 2015;90(6):756\u201364.","DOI":"10.1016\/j.mayocp.2015.03.025"},{"key":"2026091518345058771_j_jcas-2026-0008_ref_015","doi-asserted-by":"crossref","unstructured":"Marcheselli R, Bari A, et al. Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: results of a large multicenter study involving 990 patients. Hematol Oncol. 2017;35(4):561\u20136.","DOI":"10.1002\/hon.2359"},{"key":"2026091518345058771_j_jcas-2026-0008_ref_016","doi-asserted-by":"crossref","unstructured":"Rueda Dominguez A, Alfaro Lizaso J, et al. SEOM clinical guidelines for the treatment of Hodgkin\u2019s lymphoma. Clin Transl Oncol. 2015;17(12):1005\u201313.","DOI":"10.1007\/s12094-015-1429-1"},{"key":"2026091518345058771_j_jcas-2026-0008_ref_017","doi-asserted-by":"crossref","unstructured":"Johnson P, Federico M, et al. Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin\u2019s Lymphoma. N Engl J Med. 2016;374(25):2419\u201329.","DOI":"10.1056\/NEJMoa1510093"},{"key":"2026091518345058771_j_jcas-2026-0008_ref_018","doi-asserted-by":"crossref","unstructured":"Ali S, Basit A, et al. Chemotherapy alone or combined chemotherapy and involved field radiotherapy in favorable risk early-stage classical Hodgkin lymphoma-a 10 years experience. Pak J Med Sci. 2016;32(6):1408\u201313.","DOI":"10.12669\/pjms.326.11080"},{"key":"2026091518345058771_j_jcas-2026-0008_ref_019","doi-asserted-by":"crossref","unstructured":"Jacob LA, Begum T, et al. Clinical Profile and Outcome of Adult Classical Hodgkin\u2019s Lymphoma: Real World Single Centre Experience. Indian J Hematol Blood Transfus. 2024;40(3):392\u20139.","DOI":"10.1007\/s12288-024-01735-9"},{"key":"2026091518345058771_j_jcas-2026-0008_ref_020","doi-asserted-by":"crossref","unstructured":"Iftikhar I, Abbas M, et al. Real-World Outcomes of PET-Adapted Treatment for Classic Hodgkin\u2019s Lymphoma: A Study From a Single Tertiary Care Center. Cureus. 2025;17(5):e83836.","DOI":"10.7759\/cureus.83836"},{"key":"2026091518345058771_j_jcas-2026-0008_ref_021","doi-asserted-by":"crossref","unstructured":"Rose A, Grajales-Cruz A, et al. Classical Hodgkin Lymphoma: Clinicopathologic Features, Prognostic Factors, and Outcomes From a 28-Year Single Institutional Experience. Clin Lymphoma Myeloma Leuk. 2021;21(2):132\u20138.","DOI":"10.1016\/j.clml.2020.08.018"},{"key":"2026091518345058771_j_jcas-2026-0008_ref_022","doi-asserted-by":"crossref","unstructured":"Wen Q, Ge J, et al. Real-world evidence of ABVD-like regimens compared with ABVD in classical Hodgkin lymphoma: a 10-year study from China. J Cancer Res Clin Oncol. 2023;149(7):3989\u20134003.","DOI":"10.1007\/s00432-022-04321-6"},{"key":"2026091518345058771_j_jcas-2026-0008_ref_023","doi-asserted-by":"crossref","unstructured":"Biasoli I, Castro N, et al. Treatment outcomes for Hodgkin lymphoma: First report from the Brazilian Prospective Registry. Hematol Oncol. 2018;36(1):189\u201395.","DOI":"10.1002\/hon.2450"},{"key":"2026091518345058771_j_jcas-2026-0008_ref_024","doi-asserted-by":"crossref","unstructured":"DeBoer RJ, Shyirambere C, et al. Treatment of Hodgkin Lymphoma With ABVD Chemotherapy in Rural Rwanda: A Model for Cancer Care Delivery Implementation. JCO Glob Oncol. 2020;6: 1093\u2013102.","DOI":"10.1200\/GO.20.00088"},{"key":"2026091518345058771_j_jcas-2026-0008_ref_025","doi-asserted-by":"crossref","unstructured":"Bhurani D, Nair R, et al. Real-World Outcomes of Hodgkin Lymphoma: A Multi-Centric Registry From India. Front Oncol. 2021;11:799948.","DOI":"10.3389\/fonc.2021.799948"},{"key":"2026091518345058771_j_jcas-2026-0008_ref_026","doi-asserted-by":"crossref","unstructured":"Shafi RG, Al-Mansour MM, et al. Hodgkin Lymphoma Outcome: A Retrospective Study from 3 Tertiary Centers in Saudi Arabia. Oncol Res Treat. 2017;40(5):288\u201392.","DOI":"10.1159\/000460819"},{"key":"2026091518345058771_j_jcas-2026-0008_ref_027","doi-asserted-by":"crossref","unstructured":"Boo YL, Ting HSY, et al. Clinical features and treatment outcomes of Hodgkin lymphoma: A retrospective review in a Malaysian tertiary hospital. Blood Res. 2019;54(3):210\u20137.","DOI":"10.5045\/br.2019.54.3.210"},{"key":"2026091518345058771_j_jcas-2026-0008_ref_028","doi-asserted-by":"crossref","unstructured":"Cuccaro A, Bartolomei F, et al. Prognostic factors in hodgkin lymphoma. Mediterr J Hematol Infect Dis. 2014;6(1): e2014053.","DOI":"10.4084\/mjhid.2014.053"},{"key":"2026091518345058771_j_jcas-2026-0008_ref_029","doi-asserted-by":"crossref","unstructured":"Cellini A, Cavarretta CA, et al. Baseline prognostic predictors in classical Hodgkin Lymphoma: a retrospective, single-center analysis on patients treated with PET\/CT-guided ABVD. Front Oncol. 2024;14:1419118.","DOI":"10.3389\/fonc.2024.1419118"}],"container-title":["Journal of Cancer and Allied Specialties"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/jcas-2026-0008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:35:09Z","timestamp":1789497309000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/jcas-2026-0008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,6,29]]},"published-print":{"date-parts":[[2026,3,1]]}},"alternative-id":["10.2478\/jcas-2026-0008"],"URL":"https:\/\/doi.org\/10.2478\/jcas-2026-0008","relation":{},"ISSN":["2411-989X"],"issn-type":[{"value":"2411-989X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,1]]}}}